Featured Research

from universities, journals, and other organizations

Vandetanib: Hint of minor added benefit in people aged under 65 years, greater harm in people aged over 65 years

Date:
October 1, 2013
Source:
Institute for Quality and Efficiency in Health Care
Summary:
Vandetanib (trade name: Caprelsa) has been approved in Germany since February 2012 for the treatment of adult patients who have a particular form of aggressive thyroid cancer. On the inclusion of additional study data subsequently provided by the drug manufacturer in the commenting procedure, the German Institute for Quality and Efficiency in Health Care (IQWiG) came to a different conclusion in an addendum: According to the findings, there is a hint of a minor added benefit in people aged under 65 years, but a hint of greater harm (lesser benefit) in older patients in comparison with standard therapy ("best supportive care").

Vandetanib (trade name: Caprelsa) has been approved in Germany since February 2012 for the treatment of adult patients who have a particular form of aggressive thyroid cancer. On the inclusion of additional study data subsequently provided by the drug manufacturer in the commenting procedure, the German Institute for Quality and Efficiency in Health Care (IQWiG) came to a different conclusion in an addendum: According to the findings, there is a hint of a minor added benefit in people aged under 65 years, but a hint of greater harm (lesser benefit) in older patients in comparison with standard therapy ("best supportive care").

Related Articles


Additional analyses on pain and side effects

In IQWiG's dossier assessment from June 2013, important data for the harm side were missing. The Institute was therefore unable to balance positive and negative effects, and could therefore not accord an added benefit.

In the commenting procedure conducted by the Federal Joint Committee (G-BA), the pharmaceutical company now submitted additional analyses both on side effects (adverse events) and on the degree of pain. The G-BA subsequently commissioned the Institute to investigate whether, using these additional data, an added benefit of vandetanib is proven with regards to morbidity (symptoms, here: pain) and the uncertainties regarding harm are resolved.

Pain rated as severe or serious

The dossier assessment concluded that pain occurs later or gets worse later in patients aged under 65 years if they are treated with vandetanib. In people aged over 65 years, however, there was no difference in comparison with "best supportive care."

The data provided in the manufacturer's dossier did not allow to rate the severity of the pain. The additional analysis now showed that this pain in patients with this kind of pain progression is to be rated as "severe" or "serious" symptoms. IQWiG therefore considers there to be a hint of an added benefit, the extent of which is to be rated as "considerable" -- and not only "minor" as in the dossier assessment from June 2013.

More side effects under vandetanib

The additional analysis on side effects (adverse events) now allowed to assess the data although the patients in the two study arms were treated and observed for different lengths of time. It showed that vandetanib causes side effects more frequently than "best supportive care" -- independent from the patients' age. This applies to severe adverse events and skin rash. There was no difference between the study arms regarding serious adverse events and discontinuations of treatment due to side effects. IQWiG rated the extent of harm as "major" (severe adverse events) and "considerable" (skin rash).

People aged under 65 years: negative effects do not outweigh positive effects

IQWiG considers there to be both positive and negative effects in people aged under 65 years: The delay in pain progression is not outweighed by more frequent side effects. But IQWiG downgraded the extent of added benefit from "considerable" to "minor."

The assessment only found negative effects in the group of people aged over 65 years: There is only "major" and "considerable" harm in the form of side effects.

Overall, IQWiG concludes that there is a hint of minor added benefit in patients aged under 65 years, but a hint of lesser benefit in patients aged over 65 years of vandetanib compared with "best supportive care."

G-BA decides on the extent of added benefit

The dossier assessment is part of the overall procedure for early benefit assessment conducted by the G-BA. After publication of the manufacturers' dossiers and the IQWiG dossier assessments, the G-BA conducted commenting procedures, in which the manufacturer submitted additional information. The G-BA subsequently commissioned IQWiG to undertake a new assessment, with the additional data included.

If, in the course of the discussions on a commission of the G-BA, a need for further revision arises, IQWiG presents its report in the form of an addendum. The Institute sent the addendum on vandetanib to the contracting agency on 8 August 2013. The G-BA then decides on the extent of the added benefit in each case, thus completing the early benefit assessment.


Story Source:

The above story is based on materials provided by Institute for Quality and Efficiency in Health Care. Note: Materials may be edited for content and length.


Cite This Page:

Institute for Quality and Efficiency in Health Care. "Vandetanib: Hint of minor added benefit in people aged under 65 years, greater harm in people aged over 65 years." ScienceDaily. ScienceDaily, 1 October 2013. <www.sciencedaily.com/releases/2013/10/131001091641.htm>.
Institute for Quality and Efficiency in Health Care. (2013, October 1). Vandetanib: Hint of minor added benefit in people aged under 65 years, greater harm in people aged over 65 years. ScienceDaily. Retrieved October 31, 2014 from www.sciencedaily.com/releases/2013/10/131001091641.htm
Institute for Quality and Efficiency in Health Care. "Vandetanib: Hint of minor added benefit in people aged under 65 years, greater harm in people aged over 65 years." ScienceDaily. www.sciencedaily.com/releases/2013/10/131001091641.htm (accessed October 31, 2014).

Share This



More Health & Medicine News

Friday, October 31, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Melafind: Spotting Melanoma Without a Biopsy

Melafind: Spotting Melanoma Without a Biopsy

Ivanhoe (Oct. 31, 2014) The MelaFind device is a pain-free way to check suspicious moles for melanoma, without the need for a biopsy. Video provided by Ivanhoe
Powered by NewsLook.com
Battling Multiple Myeloma

Battling Multiple Myeloma

Ivanhoe (Oct. 31, 2014) The answer isn’t always found in new drugs – repurposing an ‘old’ drug that could mean better multiple myeloma treatment, and hope. Video provided by Ivanhoe
Powered by NewsLook.com
Chronic Inflammation and Prostate Cancer

Chronic Inflammation and Prostate Cancer

Ivanhoe (Oct. 31, 2014) New information that is linking chronic inflammation in the prostate and prostate cancer, which may help doctors and patients prevent cancer in the future. Video provided by Ivanhoe
Powered by NewsLook.com
Sickle Cell: Stopping Kids’ Silent Strokes

Sickle Cell: Stopping Kids’ Silent Strokes

Ivanhoe (Oct. 31, 2014) Blood transfusions are proving crucial to young sickle cell patients by helping prevent strokes, even when there is no outward sign of brain injury. Video provided by Ivanhoe
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins